Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir - Wikidata - wikimedia - TriplyDB

Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir

Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir

http://www.wikidata.org/entity/Q35002453

about

Reliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical data Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo.Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity.CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy.Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction.Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.Pharmacokinetic Interaction Between Isavuconazole and a Fixed-Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects.Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir.Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat.Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR.Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model.Identification of cytochrome P450s involved in the metabolism of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1) using human recombinant enzymes and rat liver microsomes in vitro.Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications.VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.

P2860

Q30856965-A75C9131-6388-4E35-A60A-2853B9D6A2EB Q34057466-D0CB02B0-70B1-4A45-BDDD-0F426A2172ED Q34217770-26E1F565-00B0-4A76-BFD8-3510FCC74879 Q34330504-793DCAAE-6D83-4CF2-994F-92BBF9C8E5B5 Q34437996-61F75DE4-E970-4C8B-9584-08396DD90191 Q34718314-0A2F4F80-C750-41D4-88A6-74D39A840F76 Q35579558-8E0D863A-151E-4A4B-81BF-EDB25022E7C3 Q35776626-55619AFD-067D-4EDE-A961-2865C570C899 Q36072448-4EE82C09-E893-4B8A-96FF-5B42940F5085 Q36599597-7B1C52CC-8C2E-487C-980E-8163D28EF023 Q36652680-2AB74C93-72A7-4E63-9CEF-B0430578BC8A Q36712344-B8902371-0ACC-45D7-9613-510599625EC8 Q36785839-C2D076A7-0A8F-457E-92E7-2B0B3E0C0509 Q37193089-9922590D-4024-44DE-851D-0D134A2C7F54 Q37207816-AD8EEB34-5DEC-420A-9145-AD375EB02F48 Q37325606-AE7FF22A-1F7D-4322-9BBA-A074EB54B51E Q37631771-2F62F6B9-1149-47EF-B686-510BA8B6B908 Q38836056-5D3AFCF9-35CF-469C-9B68-84743669F26B Q38958223-0BF89DE5-E156-4956-BBBF-15FD48D0C4B2 Q39080596-B0A6CCAE-8124-4F93-ABDA-11968C9FF82D Q40171626-B9265168-39B8-4724-8599-3E6DA7D48FB9 Q47901866-B57FBB93-9E48-48AD-AC82-D8482FB51094 Q47909730-EBE7069D-6D05-44FC-980C-EC205AF55DEE Q48500206-2E6E23C4-2A47-4C44-8BD2-3D820EA848FF Q50050263-4F3E74FC-42B2-42E5-A33F-2C58E47A331B Q51031739-4290B280-1CE1-4229-BA30-B7DD945361A5 Q52312048-83D086FC-7613-49C0-9A5C-7794A4953F12 Q53081552-C58AE400-2A65-4E71-9783-A58C2591864C

P2860

Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir

http://www.wikidata.org/entity/Q35002453

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Complex drug interactions of H ...... 3A by ritonavir or nelfinavir

@ast

Complex drug interactions of H ...... 3A by ritonavir or nelfinavir

@en

type

label

Complex drug interactions of H ...... 3A by ritonavir or nelfinavir

@ast

Complex drug interactions of H ...... 3A by ritonavir or nelfinavir

@en

prefLabel

Complex drug interactions of H ...... 3A by ritonavir or nelfinavir

@ast

Complex drug interactions of H ...... 3A by ritonavir or nelfinavir

@en

P1433

Q35002453-110B3907-DF9E-4941-A305-A0BDE8E77618

P1476

Q35002453-7DD6B243-B0A5-45BE-BA3C-6717A2FBE991

P2093

Q35002453-02E2E7CA-6092-423D-A690-CCF56B71BF3D

Q35002453-1BA6560A-2090-4D5E-9D95-934B8411A60A

Q35002453-32A97FFF-6EFC-4B9C-931A-B06FC6822AB8

Q35002453-AE3CC828-F179-4C07-AEE4-8327CC2A24CF

Q35002453-C32AF09D-CA54-4530-BA43-269451ED0B16

Q35002453-EBE9A472-6178-4AB7-A180-01A562819A0E

P2860

Q35002453-0116AE68-4BA1-4CA3-9B2E-33D91EF50E3E

Q35002453-0AC12407-B3F3-464D-A59E-CF0F39C7EEA6

Q35002453-196164D8-D831-434F-BD0B-ACAFD5963565

Q35002453-33398554-AD97-4216-8588-C235DF711FE2

Q35002453-3AF8DB16-D0F9-4B1A-9EE2-3E4BA09701F6

Q35002453-4A2951E2-7CEE-44B6-9D4E-6CB3F75AABF6

Q35002453-5E91FA66-F472-4D06-B8BB-5744529B00C4

Q35002453-62E525A8-3B37-46ED-A77B-DBBB391AE6F4

Q35002453-6837B799-78EF-46D4-AF1A-11DF4645CDD3

Q35002453-702A7E4F-FFDC-4746-8424-B6EA9101FF52

P304

Q35002453-E2AF68E7-C968-4323-8E5E-9662D21B56CD

P31

Q35002453-8FA9123D-B093-4BC5-9BFE-D5252BF9392C

P356

Q35002453-C992FC43-6776-42EA-815C-2A4D5914014C

P433

Q35002453-BBE08C2C-6A02-439B-AD4A-C87791664EFB

P478

Q35002453-B29BEA7B-5DA1-41FB-B85E-9D92777DD644

P577

Q35002453-60091C00-56DD-4BF5-9065-EB074F94BA82

P5875

Q35002453-A4764189-0D45-4A47-882D-CFED3527AD13

P698

Q35002453-7E42EC86-434D-4D56-85FA-E65A564A6BF3

P932

Q35002453-AFDD575A-07E4-46F7-AD1E-43541D650E66

P356

P1433

Drug Metabolism and Disposition

P1476

Complex drug interactions of H ...... 3A by ritonavir or nelfinavir

@en

P2093

Ann C Collier

http://www.w3.org/2001/XMLSchema#string

Brian J Kirby

http://www.w3.org/2001/XMLSchema#string

Dale Whittington

http://www.w3.org/2001/XMLSchema#string

Evan D Kharasch

http://www.w3.org/2001/XMLSchema#string

Jashvant D Unadkat

http://www.w3.org/2001/XMLSchema#string

Kenneth E Thummel

http://www.w3.org/2001/XMLSchema#string

P2860

Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice

Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities

Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes.

Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.

Nelfinavir: an update on its use in HIV infection.

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

Impact of ignoring extraction ratio when predicting drug-drug interactions, fraction metabolized, and intestinal first-pass contribution.

Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

Interaction between lopinavir/ritonavir and warfarin.

P304

1070-1078

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/DMD.110.037523

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50398649

http://www.w3.org/2001/XMLSchema#string

P698

21406602

http://www.w3.org/2001/XMLSchema#string

P932

3100903

http://www.w3.org/2001/XMLSchema#string